Fate Therapeutics (FATE) Cash from Operations (2012 - 2026)

Fate Therapeutics has reported Cash from Operations for 15 years, with the latest figure at 30822000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 8.83% year-over-year to 30822000.0; the trailing twelve-month figure through Mar 2026 stood at 103097000.0 (up 16.41% YoY), and the FY2025 full-year result was 106084000.0, up 13.66% from the prior year.
• Cash from Operations for Q1 2026 stood at 30822000.0, down from 23314000.0 in the prior quarter.
• The five-year high for Cash from Operations was 23314000.0 in Q4 2025, with the low at 75389000.0 in Q4 2022.
• Historically, Cash from Operations has averaged 37661823.53 across 5 years, with a median of 32306000.0 in 2024.
• Annual changes were most pronounced in 2022 — Cash from Operations slumped 138.46% — and 2023, when it soared 55.33%.
• Fate Therapeutics' Cash from Operations stood at 75389000.0 in 2022, then soared by 51.4% to 36637000.0 in 2023, then grew by 24.12% to 27799000.0 in 2024, then climbed by 16.13% to 23314000.0 in 2025, then tumbled by 32.2% to 30822000.0 in 2026.
• The last three Cash from Operations figures came in at 30822000.0 (Q1 2026), 23314000.0 (Q4 2025), and 24374000.0 (Q3 2025), per Business Quant data.